Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 50: 769-772, 2004; 10.1373/clinchem.2003.028241
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lucas, T.
Right arrow Articles by Wacheck, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lucas, T.
Right arrow Articles by Wacheck, V.
Related Collections
Right arrow Molecular Diagnostics and Genetics
(Clinical Chemistry. 2004;50:769-772.)
© 2004 American Association for Clinical Chemistry, Inc.

Technical Briefs

Combination Allele-Specific Real-Time PCR for Differentiation of ß2-Adrenergic Receptor Coding Single-Nucleotide Polymorphisms

Trevor Lucas1,2,1,a, Doris Losert1,1, Matthew Allen1,2, Julius Halaschek-Wiener1, Barbara Pratscher1,2, Cornelia Friedrich1,2, Markus Wolschek1, Gabriele Fuchsjäger-Mayrl1,3, Leopold Schmetterer1,4, Hubert Pehamberger2, Markus Müller1 and Volker Wacheck1

1 Department of Clinical Pharmacology, Section of Experimental Oncology/Molecular Pharmacology,2 Department of Dermatology, Division of General Dermatology, and3 Department of Ophthalmology, University of Vienna, Vienna, Austria;4 Institute of Medical Physics, Vienna, Austria

aaddress correspondence to this author at: Department of Clinical Pharmacology, University of Vienna, Vienna General Hospital, Waehringer Guertel 18-20, Vienna, Austria A-1090; fax 43-1-40400-2998, e-mail trevor.lucas@univie.ac.at

The first 300 words of the full text of this article appear below.

The ß2-adrenergic receptor (ADRB2) is a GTP-binding-protein-coupled receptor produced by a wide variety of cell types. Stimulation of ADRB2 by catecholamines or synthetic therapeutic agonists promotes physiologic processes as varied as smooth muscle relaxation and lipolysis. Stimulation of ADRB2 is characterized by rapid desensitization governed by receptor internalization, which plays a direct role in the response to catecholamines and synthetic agonists governing cellular responses (1).

ADRB2 is transcribed from an intronless gene on chromosome 5q32 that encodes a 413-residue protein with 7 transmembrane domains (2). Within the ADRB2 gene, 13 single-nucleotide polymorphisms (SNPs) have been identified (3), including 3 coding ADRB2 missense polymorphisms that alter protein function (4). A threonine-to-isoleucine (T164I) substitution in the fourth transmembrane domain alters ligand binding and decreases adenylate cyclase activation but is rare in the population (5). The extracellular domain N-terminal arginine-to-glycine (R16G) and glutamine-to-glutamic acid (Q27E) polymorphisms are common and widely distributed within the population. These polymorphisms strongly influence the degree of agonist-mediated receptor down-regulation. Whereas Q27E induces complete resistance to down-regulation in combination with R16, R16G increases agonist-mediated receptor down-regulation in both haplotypes (5).

The importance of developing rapid ADRB2 screening protocols that differentiate codon 16/27 diplotypes is emphasized by the number of studies linking these genotypes to clinical and pharmacologic responses. SNPs representing the partial haplotype at codons 16 and 27 are variously associated with altered vasodilation (6) and high blood pressure (7), play roles in the development of type II diabetes (8), and have been linked to preterm delivery (9), agonist desensitization (10), albuterol responses (11), increased IgE in asthmatic families (12), obesity (13), hypertriglyceridemia, and development of fatty liver (14. . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 J. Mol. Diagn.Home page
M. F. Sabato, A.-M. Irani, B. L. Bukaveckas, L. B. Schwartz, D. S. Wilkinson, and A. Ferreira-Gonzalez
A Simple and Rapid Genotyping Assay for Simultaneous Detection of Two ADRB2 Allelic Variants Using Fluorescence Resonance Energy Transfer Probes and Melting Curve Analysis
J. Mol. Diagn., May 1, 2008; 10(3): 258 - 264.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.